Serum interleukin 6 levels as a useful prognostic predictor of clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease

Autor: Kenichi Sawada, Shin Okuyama, Ayumi Omokawa, Atsushi Komatsuda, Hideki Wakui, Masaru Togashi, Mizuho Nara
Rok vydání: 2013
Předmět:
Zdroj: Modern Rheumatology. 24:633-636
ISSN: 1439-7609
1439-7595
DOI: 10.3109/14397595.2013.844390
Popis: Objectives Clinically amyopathic dermatomyositis (CADM) is considered as the subtype of dermatomyositis with amyopathy or hypomyopathy. Rapidly progressive interstitial lung disease (RP-ILD) is treatment-resistant and life-threatening in patients with CADM. Since useful markers for early diagnosis are necessary for early treatment in CADM patients with RP-IPD, this study aimed to investigate the differences of clinical and laboratory characteristics between alive patients (group A) and patients who died (group D).Methods Eleven patients with CADM complicating with RP-ILD were enrolled. Clinical manifestations and laboratory data before treatment were compared between group A and group D.Results Among them, six were alive and five died after treatment for RP-ILD. Serum IL-6 levels in group D were significantly higher than those in group A (median 19.7 vs 7.15 pg/ml; P=0.008). The stepwise regression analysis showed that IL-6 was the only prognostic factor significantly (p=0.035). Kaplan-Meier estimates showed that patient survivals were better in patients with IL-6 < 9pg/ml than those with > 9pg/ml (p=0.039). Other laboratory data were not different statistically between two groups.Conclusions Serum IL-6 may predict the prognosis of patients with CADM having RP-ILD. Patients with IL-6 >9pg/ml should be treated by the more aggressive immunosuppressive therapy.
Databáze: OpenAIRE
Externí odkaz: